FORCE Leads the Charge for Medicaid Coverage of Genetic Testing
Genetic testing for increased susceptibility to breast, ovarian, and other cancers has become the standard of care for prevention and risk management in the U.S. Medicaid coverage of health services, however, is managed independently by each state. Of the 50 state Medicaid programs, only 4—Alabama, Rhode Island, North Carolina, and South Carolina—do not cover genetic counseling and/or testing for inherited genetic mutations such as BRCA1 or BRCA2.
FORCE learned that the North Carolina Division of Medical Assistance (DMA) is reviewing its policy on offering genetic testing. We mobilized quickly to write comments and secured the support of over 30 partner nonprofit and medical professional organizations in an effort to encourage NC Medicaid to offer this invaluable service to its enrollees. Read the comments submitted on March 23, 2018.
The vast majority of health insurers see the value of identifying individuals who may carry an inherited genetic mutation that causes increased risk of cancer (if that person meets certain personal and/or family health history criteria). In fact, under the Affordable Care Act (ACA), many insurance plans are required to cover BRCA genetic testing for women who qualify and other specified preventive services with no copay or cost-sharing.
Medicaid and Medicare are not bound by the ACA mandate. Most Medicare regions cover BRCA testing only if a woman has already been diagnosed with cancer. Four regions, representing 19 states, have more expansive policies that include multigene panel testing if more than one mutation may be indicated, as well as testing for men.
FORCE continues to advocate that all Americans—regardless of gender, cancer status, economic situation, or health insurance provider—should have access to evidence-based preventive services including, but not limited to:
- Genetic counseling and testing for:
- unaffected carriers/previvors and survivors
- women and men
- Appropriate screening and surgical interventions as recommended by the National Comprehensive Cancer Network (NCCN):
- breast cancer screening with mammograms and breast MRIs
- ovarian cancer screening with CA125 and transvaginal ultrasound
- prostate cancer screening with PSA testing and digital rectal exam
- risk-reducing salpingo-oophorectomy or hysterectomy
- prophylactic mastectomy
- chemoprevention or risk-reducing medication for breast and ovarian cancer
We are hopeful that NC Medicaid will institute a policy that includes coverage of genetic counseling and testing for those who should receive it. Moving ahead, we plan to work with the other three state Medicaid programs that currently fail to provide access to cancer genetic services.
9/9/2021 - Joined 131 groups in a letter to Congress outlining recommendations to improve prescription drug affordability in Medicare Part D.
7/21/2021 - Lisa Schlager, FORCE VP of Public Policy, made remarks in support of the Protecting Access to Lifesaving Screenings (PALS) Act, which aims to preserve access to screening mammograms with no cost-sharing for women ages 40-49.